Benítez J, Ladero J M, Fernández-Gundín M J, Llerena A, Cobaleda J, Martínez C, Muñoz J J, Vargas E, Prados J, González-Rozas F
Department of Pharmacology, University of Extremadura, Badajoz, Spain.
Ann Med. 1990 Jun;22(3):157-60. doi: 10.3109/07853899009147261.
The oxidative polymorphism of debrisoquine has been determined in 125 patients with bladder cancer and in 556 healthy control subjects; 96.6% of patients and 93.9% of controls with a metabolic ratio of debrisoquine less than 12.6 were classified as extensive metabolizers of debrisoquine (P = NS). The distribution of frequencies of metabolic ratio values tended to have lower values in the patients (P less than 0.05), reflecting a higher oxidative rate of debrisoquine in urothelioma patients that cannot be explained solely in terms of enzymatic induction by drugs, tobacco or alcohol. Patients with a high occupational risk for urothelioma had lower metabolic ratio values (P = 0.03). Our results suggest that oxidative polymorphism of debrisoquine might be related to the pathogenesis of bladder cancer.
已对125例膀胱癌患者和556名健康对照者进行了异喹胍氧化多态性测定；异喹胍代谢率低于12.6的患者中有96.6%以及对照者中有93.9%被归类为异喹胍的快代谢者（P=无显著性差异）。代谢率值的频率分布在患者中往往较低（P<0.05），这反映出尿路上皮瘤患者中异喹胍的氧化速率较高，而这不能仅用药物、烟草或酒精的酶诱导来解释。尿路上皮瘤职业风险高的患者代谢率值较低（P=0.03）。我们的结果表明，异喹胍氧化多态性可能与膀胱癌的发病机制有关。
